AbCellera Biologics Inc.
ABCL
$2.33
-$0.065-2.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -11.24% | -36.13% | -107.42% | -192.84% | -192.35% |
| Total Depreciation and Amortization | 110.39% | 220.78% | 118.50% | 13.75% | 25.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.07% | -95.84% | -60.04% | 1.90% | -9.19% |
| Change in Net Operating Assets | -295.41% | -196.39% | 81.35% | -90.04% | -55.66% |
| Cash from Operations | -147.41% | -1,908.11% | 23.86% | -131.20% | -115.82% |
| Capital Expenditure | -1.88% | -3.14% | -17.88% | -21.02% | -8.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 238.60% | 199.70% | 129.78% | 111.00% | 48.87% |
| Cash from Investing | 154.91% | 128.70% | 109.29% | 91.26% | 37.30% |
| Total Debt Issued | 16.46% | 82.79% | 2,673.62% | 1,584.77% | 320.69% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 46.30% | 46.30% | 95.27% | 202.45% | -- |
| Repurchase of Common Stock | -46.30% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 40.92% | 29.74% | 33.60% | -81.85% | 71.85% |
| Cash from Financing | 23.30% | 78.56% | 5,356.01% | 1,205.74% | 736.12% |
| Foreign Exchange rate Adjustments | -544.31% | 631.30% | 89.23% | 100.22% | 106.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 109.06% | 77.15% | 94.85% | 80.23% | -193.72% |
